Vacuolin-1
目录号 : GC10325
An inhibitor of lysosomal exocytosis
Cas No.:351986-85-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Vacuolin-1 is a potent and cell-permeable inhibitor of Ca2+-dependent lysosomal exocytosis [1].
Exocytic fusion of lysosomes triggered by plasma membrane damage is the major source of the membrane required for resealing. Lysosomal markers appear at the cell surface or are released into the medium on transient elevation of cytosolic Ca2+, including that induced by plasma membrane disruption [1].
Vacuolin-1 is a cell-permeable blocker of Ca2+-dependent lysosomal exocytosis induced by ionomycin or plasma membrane wounding. In HeLa cells, 5 or 10 μM Vacuolin-1 reduced the release of lysosomal β-hexosaminidase. Vacuolin-1 also blocked the ionomycin-induced, Ca2+-dependent cell surface appearance of the luminal epitope from the lysosomal membrane protein, Lamp-1, a marker for fusion between the limiting membranes of lysosomes and the cell surface. Thus, vacuolin-1 blocks the Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal contents. While vacuolin-1 had no effect on the fusion of enlargeosomes with the plasma membrane. Other cell structures and membrane trafficking functions were also unaffected [1].
Reference:
[1]. Cerny J, Feng Y, Yu A, et al. The small chemical vacuolin-1 inhibits Ca2+-dependent lysosomal exocytosis but not cell resealing. EMBO Rep. 2004 Sep;5(9):883-8.
| Cas No. | 351986-85-1 | SDF | |
| 化学名 | 3-iodo-2-[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone, benzaldehyde | ||
| Canonical SMILES | IC1=CC(/C=N/NC2=NC(N(C3=CC=CC=C3)C4=CC=CC=C4)=NC(N5CCOCC5)=N2)=CC=C1 | ||
| 分子式 | C26H24IN7O | 分子量 | 577.4 |
| 溶解度 | ≤5mg/ml in DMSO;3mg/ml in dimethyl formamide | 储存条件 | Store at -20°C, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7319 mL | 8.6595 mL | 17.319 mL |
| 5 mM | 0.3464 mL | 1.7319 mL | 3.4638 mL |
| 10 mM | 0.1732 mL | 0.866 mL | 1.7319 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。